Europe Pharmaceutical Contract Development and Manufacturing Market to be worth $68.12 Billion by 2030
Meticulous Research®, a leading global market research
company, published a research report titled,
'Europe Pharmaceutical Contract Development and
Manufacturing Market by Service {Manufacturing [API, FDF
(Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics
Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to
2030.’
According to this latest
publication from Meticulous Research®,
the europe pharmaceutical contract development and manufacturing market is
expected to reach $68.12 billion by 2030 at a CAGR of 7.4% from 2023 to 2030.
The growth of the Europe pharmaceutical contract development and manufacturing
market is attributed to the rising incidence & prevalence of chronic
illness, rising awareness of overall health and treatment availability, growing
geriatric population in the region, rising pharmaceutical R&D expenditure,
low-cost manufacturing advantages, increasing government funding for drug
development and research, improving healthcare infrastructure, and growing
healthcare spending.
The lack of skilled professionals
is challenging the growth of this market. High demand for personalized
medicine, cell therapies, and gene therapies, and growth in high potency Active
Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) market in
European countries are providing opportunities for market growth.
Download Free
PDF Sample Copy of the Report (with COVID-19 Impact Analysis): https://www.meticulousresearch.com/download-sample-report/cp_id=5592
Scope of the Report:
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by Type
·
Pharmaceutical Manufacturing Services
o Active Pharmaceutical Ingredient (API) Manufacturing Services
o Finished Dosage Forms (FDF) Manufacturing Services
§ Parenteral/Injectable Manufacturing Services
§ Tablet Manufacturing Services
§ Capsule Manufacturing Services
§ Oral Liquid Manufacturing Services
§ Other Formulations
·
Drug Development Services
·
Biologics Manufacturing Services
o Active Pharmaceutical Ingredient (API) Manufacturing Services
o Finished Dosage Forms (FDF) Manufacturing Services
(Note:Other formulations include topical formulations, powders
formulations, and modified-release dosage forms)
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by End User
·
Large Pharmaceutical Companies
·
Small & Mid-Size Pharmaceutical Companies
·
Generic Pharmaceutical Companies
Europe Pharmaceutical Contract Development and Manufacturing Market Assessment, by Country
·
Germany
·
U.K.
·
France
·
Italy
·
Spain
·
Switzerland
·
Netherlands
·
Denmark
·
Rest of Europe
To Gain More
Insights into the Market with a Detailed Table of Content and Figures, Click
Here: https://www.meticulousresearch.com/product/europe-pharmaceutical-contract-development-and-manufacturing-market-5592
Key Players
The key players operating in the
Europe pharmaceutical contract development and manufacturing market are AbbVie
Inc. (U.S.), Aenova Group (Germany), Wuxi Biologics, Inc. (China), Vetter
Pharma International GmbH (Germany), Catalent, Inc. (U.S.), Lonza Group Ltd.
(Switzerland), Recipharm AB (Sweden), Almac Group (U.K.), C.H. Boehringer Sohn
Ag & Co. KG. (Germany), Eurofins Scientific (France), Curia Global, Inc.
(U.S.), Thermo Fisher Scientific, Inc. (U.S.), Evonik Industries AG (Germany),
Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), Fabbrica
Italiana Sintetici S.p.A. (Italy), and Corden Pharma GmbH (Germany).
Europe Pharmaceutical Contract Development and
Manufacturing Market: Future Outlook
The Europe pharmaceutical contract
development and manufacturing market is segmented by Type (Pharmaceutical
Manufacturing Services {Active Pharmaceutical ingredient (API) Manufacturing
Services and Finished Dosage Forms (FDF) Manufacturing Services [Parenteral/Injectable
Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing
Services, Oral Liquid Manufacturing Services, and Other Formulations]}, Drug
Development Services, and Biologics Manufacturing Services{Active
Pharmaceutical ingredient (API) Manufacturing Services and Finished Dosage
Forms (FDF) Manufacturing Services}), End User (Large Pharmaceutical Companies,
Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical
Companies), and Countries. The study also evaluates industry competitors and
analyzes their market share at the country level.
Request Customization Here: https://www.meticulousresearch.com/request-customization/cp_id=5592
Among all types studied in this report, in 2023, the pharmaceutical manufacturing services
segment is expected to account for the largest share of the Europe
pharmaceutical contract development and manufacturing market. The
pharmaceutical manufacturing services segment is further segmented into active
pharmaceutical ingredient (API) manufacturing services and finished dosage
forms (FDF) manufacturing services. The largest share of this segment is
attributed to the need to reduce manufacturing costs, to bring a new drug to
the market quickly at the lowest possible cost, the requirement for
high-quality bulk manufacturing, and the growing demand for generic drugs.
Among all end
users studied in this report, the
generic pharmaceutical companies segment is expected to register the highest
CAGR over the forecast period. The growth of this end-user segment is driven by
the increasing competition in the generic market leading to pricing pressure
and the growing inclination of these companies toward the use of cutting-edge
technologies offered by contract development and manufacturing firms.
Geographic Review
This research report
comprehensively analyzes major countries Germany, the U.K., France, Italy,
Spain, Switzerland, Netherlands, Denmark, and the Rest of Europe. In 2023,
Germany is expected to account for the largest share of the Europe
pharmaceutical contract development and manufacturing market. Germany is the
largest exporter of medicinal products and ranks among the top pharmaceutical
producers worldwide. Considering the global need for personalized medicine,
Germany has also evolved into one of the main suppliers of novel
biopharmaceuticals. This is expected to drive the country's demand for
pharmaceutical contract development and manufacturing services.
CDMOs are inaugurating newer
facilities to meet the growing demand, which is the new trend seen in the CDMOs
market in Germany. For instance, In July 2021, Richter-Helm Biologics GmbH
& Co. KG (Germany) inaugurated a new manufacturing facility in Bovenau,
Germany, to triple its biopharmaceutical production capacity.
You can Buy Report
from Here: https://www.meticulousresearch.com/Checkout/34320916
Key questions answered in the report-
·
Which are the high-growth
market segments in terms of type, end user, and country?
·
What was the historical market
for pharmaceutical contract development and manufacturing services in Europe?
·
What are the market forecasts
and estimates for the period 2023–2030?
·
What are the major drivers,
restraints, challenges, and opportunities in the Europe pharmaceutical contract
development and manufacturing market?
·
Who are the major players in
the Europe pharmaceutical contract development and manufacturing market?
Contact
Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment